

**LA JOLLA PHARMACEUTICAL COMPANY**

**Unaudited Condensed Consolidated Statements of Operations**

(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2016	2015	2016	2015
<b>Revenue</b>				
Contract revenue - related party	\$ 44	\$ 647	\$ 531	\$ 647
<b>Total revenue</b>	<b>44</b>	<b>647</b>	<b>531</b>	<b>647</b>
<b>Expenses</b>				
Research and development	16,992	7,781	42,111	19,637
General and administrative	4,349	3,353	11,868	11,122
<b>Total expenses</b>	<b>21,341</b>	<b>11,134</b>	<b>53,979</b>	<b>30,759</b>
Loss from operations	(21,297)	(10,487)	(53,448)	(30,112)
Other income, net	46	13	150	33
<b>Net loss</b>	<b>\$ (21,251)</b>	<b>\$ (10,474)</b>	<b>\$ (53,298)</b>	<b>\$ (30,079)</b>
<b>Basic and diluted net loss per share</b>	<b>\$ (1.23)</b>	<b>\$ (0.70)</b>	<b>\$ (3.10)</b>	<b>\$ (1.99)</b>
Shares used in computing basic and diluted net loss per share	17,211	14,899	17,211	15,129

**LA JOLLA PHARMACEUTICAL COMPANY**

**Condensed Consolidated Balance Sheets**  
(in thousands, except share and par value amounts)

	September 30, 2016 (Unaudited)	December 31, 2015
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 85,035	\$ 126,467
Restricted cash	200	237
Prepaid clinical expenses	105	223
Prepaid expenses and other current assets	1,396	618
<b>Total current assets</b>	<b>86,736</b>	<b>127,545</b>
Property and equipment, net	2,566	1,732
Other assets	219	70
<b>Total assets</b>	<b>\$ 89,521</b>	<b>\$ 129,347</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,998	\$ 2,506
Accrued expenses	3,917	1,224
Accrued payroll and related expenses	1,321	1,090
<b>Total current liabilities</b>	<b>7,236</b>	<b>4,820</b>
Shareholders' equity:		
Common Stock, \$0.0001 par value; 100,000,000 shares authorized, 18,254,009 and 18,244,009 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	2	2
Series C-1 <sup>2</sup> Convertible Preferred Stock, \$0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at September 30, 2016 and December 31, 2015, and liquidation preference of \$3.906 at September 30, 2016 and December 31, 2015	3,906	3,906
Series F Convertible Preferred Stock, \$0.0001 par value; 10,000 shares authorized, 2,737 shares issued and outstanding at September 30, 2016 and December 31, 2015, and liquidation preference of \$2.737 at September 30, 2016 and December 31, 2015	2,737	2,737
Additional paid-in capital	657,464	646,408
Accumulated deficit	(581,824)	(528,526)
<b>Total shareholders' equity</b>	<b>82,285</b>	<b>124,527</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 89,521</b>	<b>\$ 129,347</b>